Evidence map›Paper›PMID 31920302›Full record

ArticleInternational journal of nanomedicine2019

Verteporfin-Loaded Anisotropic Poly(Beta-Amino Ester)-Based Micelles Demonstrate Brain Cancer-Selective Cytotoxicity and Enhanced Pharmacokinetics.

James G Shamul, Sagar R Shah, Jayoung Kim, Paula Schiapparelli, Carla A Vazquez-Ramos, Ben J Lee, Kisha K Patel, Alyssa Shin, Alfredo Quinones-Hinojosa, Jordan J Green

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Charge-Stabilized Nanodiscs as a New Class of Lipid Nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2024
    Article
  9. In vivo safety evaluation method for nanomaterials for cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

James G Shamul *Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Sagar R Shah *Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Jayoung KimDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Paula SchiapparelliDepartment of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA.
Carla A Vazquez-RamosDepartment of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA.
Ben J LeeDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.ORCID 0000-0002-9395-318X
Kisha K PatelDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Alyssa ShinDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.ORCID 0000-0001-8505-9252
Alfredo Quinones-HinojosaDepartment of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA.
Jordan J GreenDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.ORCID 0000-0003-4176-3808
Johns Hopkins University · USMayo Clinic in Florida · US

Funding

Intra-Operative, Label-Free Detection of Brain Cancer Infiltration with Quantitative Optical ImagingR01CA200399 · NCI · JOHNS HOPKINS UNIVERSITY · PI LI, XINGDE, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$3.0M
A novel microfluidic device to predict brain cancer prognosis and response to therapyR01CA216855 · NCI · MAYO CLINIC JACKSONVILLE · PI KONSTANTOPOULOS, KONSTANTINOS, QUINONES-HINOJOSA, ALFREDO · 2018 to 2022
$2.4M
Gene Delivery Nanoparticles to Treat GlioblastomaR01EB016721 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2013 to 2017
$1.9M
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)R01CA195503 · NCI · MAYO CLINIC JACKSONVILLE · PI GREEN, JORDAN, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$1.9M
BMP4 Engineered Mesenchymal Stem Cell Therapy for GlioblastomaR01CA183827 · NCI · MAYO CLINIC JACKSONVILLE · PI QUINONES-HINOJOSA, ALFREDO · 2015 to 2019
$1.9M
Gene Delivery Nanoparticles to Treat GlioblastomaR01CA228133 · NCI · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2019 to 2023
$1.9M
Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapyR43CA221490 · NCI · CELL REPROGRAMMING AND THERAPEUTICS, LLC · PI ALEXANIAN, ARSHAK R, QUINONES-HINOJOSA, ALFREDO · 2018 to 2018
$300k
NCI NIH HHS R01 CA183827NCI NIH HHS R01 CA195503NCI NIH HHS R01 CA200399NCI NIH HHS R01 CA216855NCI NIH HHS R01 CA228133NCI NIH HHS R43 CA221490NIBIB NIH HHS R01 EB016721
6 · The paper itself

Abstract

backgroundNanomedicine can improve traditional therapies by enhancing the controlled release of drugs at targeted tissues in the body. However, there still exists disease- and therapy-specific barriers that limit the efficacy of such treatments. A major challenge in developing effective therapies for one of the most aggressive brain tumors, glioblastoma (GBM), is affecting brain cancer cells while avoiding damage to the surrounding healthy brain parenchyma. Here, we developed poly(ethylene glycol) (PEG)-poly(beta-amino ester) (PBAE) (PEG-PBAE)-based micelles encapsulating verteporfin (VP) to increase tumor-specific targeting.

methodsBiodegradable, pH-sensitive micelles of different shapes were synthesized via nanoprecipitation using two different triblock PEG-PBAE-PEG copolymers varying in their relative hydrophobicity. The anti-tumor efficacy of verteporfin loaded in these anisotropic and spherical micelles was evaluated in vitro using patient-derived primary GBM cells.

resultsFor anisotropic micelles, uptake efficiency was ~100% in GBM cells (GBM1A and JHGBM612) while only 46% in normal human astrocytes (NHA) at 15.6 nM VP (p ≤ 0.0001). Cell killing of GBM1A and JHGBM612 vs NHA was 52% and 77% vs 29%, respectively, at 24 hrs post-treatment of 125 nM VP-encapsulated in anisotropic micelles (p ≤ 0.0001), demonstrating the tumor cell-specific selectivity of VP. Moreover, anisotropic micelles showed an approximately fivefold longer half-life in blood circulation than the analogous spherical micelles in a GBM xenograft model in mice. In this model, micelle accumulation to tumors was significantly greater for anisotropic micelle-treated mice compared to spherical micelle-treated mice at both 8 hrs (~1.8-fold greater, p ≤ 0.001) and 24 hrs (~2.1-fold greater, p ≤ 0.0001).

conclusionOverall, this work highlights the promise of a biodegradable anisotropic micelle system to overcome multiple drug delivery challenges and enhance efficacy and safety for the treatment of brain cancer.

Indexed as

MicellesAnimalsAnisotropyAstrocytesBrain NeoplasmsCell DeathCell Line, TumorDrug CarriersDrug LiberationEndocytosisGlioblastomaHumansHydrogen-Ion ConcentrationMice, NudePolyethylene GlycolsPolymersDrug CarriersMicellespoly(beta-amino ester)Polyethylene GlycolsPolymersVerteporfinanisotropicGBMmicellePBAEPEGpoly(beta-amino ester)poly(ethylene glycol)verteporfin

Identifiers

PMID31920302
PMCPMC6935022
OpenAlexW2995215192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.